Jury orders J&J unit to pay $8.3 million in metal hip trial
(Reuters) - A Los Angeles jury ordered Johnson & Johnson's DePuy orthopedic unit to pay more than $8 million in damages in the first trial of nearly 11,000 lawsuits filed...
Home > Reviews
All Stories
Jury orders J&J unit to pay $8.3 million in metal hip trial
(Reuters) - A Los Angeles jury ordered Johnson & Johnson's DePuy orthopedic unit to pay more than $8 million in damages in the first trial of nearly 11,000 lawsuits filed...
Analysis: U.S. states race to capture online gaming bonanza
(Reuters) - New Jersey Governor Chris Christie this week finally approved online gaming in the Garden State. Now comes the hard part: banding together with other states to attract more...
J&J metal hip failed because of toxic debris – expert at trial
LOS ANGELES (Reuters) - Toxicity caused by debris from a metal-on-metal hip implant meant that the device had to be removed from a 66-year-old man who is suing manufacturer Johnson...
J&J metal hip failed because of toxic debris – expert at trial
LOS ANGELES (Reuters) - Toxicity caused by debris from a metal-on-metal hip implant meant that the device had to be removed from a 66-year-old man who is suing manufacturer Johnson...
Arguments in first J&J hip implant trial begin in Los Angeles
Los Angeles (Reuters) - Johnson & Johnson was aware of defects when it started selling its now-recalled metal hip implants in 2004, lawyers said on Friday during opening arguments in...
X and Z in favor as companies name new drugs
(Reuters) - They may be difficult to pronounce, but pharmaceutical companies eager to grab the attention of doctors and patients are returning to drug names starting with X and Z....
Arguments in first J&J hip implant trial begin in Los Angeles
Los Angeles (Reuters) - Johnson & Johnson was aware of defects when it started selling its now-recalled metal hip implants in 2004, lawyers said on Friday during opening arguments in...
X and Z in favor as companies name new drugs
(Reuters) - They may be difficult to pronounce, but pharmaceutical companies eager to grab the attention of doctors and patients are returning to drug names starting with X and Z....
More pressure to justify cost of cancer drugs versus benefits
(Reuters) - Medical providers have begun to think more about cost, as well as safety and effectiveness, when they decide on cancer treatments. In the past, pharmaceutical companies could launch...